OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company, announced it will present Phase 2 data for its dry eye disease treatment, OK-101, at the Dry Horizons Symposium. This event is a partner meeting of the Association for Research in Vision and Ophthalmology (ARVO), scheduled for May 3, 2024, in Seattle, WA.
Advertisement Go to Proactive UK Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Advertisement Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Advertisement Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com